Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 97

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Huntington's disease

Not recruiting

Safety and Tolerability Study of AB-1001 Brain Injection in Adults with Early Huntington's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid
  • Sponsor:AskBio France

Spinal muscular atrophy

Not recruiting

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and TYPE 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Anaesthesia

Not recruiting

Study on the Effectiveness of Chloroprocaine Gel and Oxybuprocaine Drops for Eye Anesthesia in Children Needing Eye Exams

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Oxybuprocaine
  • Sponsor:Sintetica S.A.

Alternating hemiplegia of childhood

Not recruiting

Study on Oxygen and Nitrous Oxide for Treating Dystonic and Plegic Attacks in Children with Alternating Hemiplegia

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuromyelitis optica spectrum disorder

Not recruiting

Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Amyotrophic lateral sclerosis

Not recruiting

Study on the Effects of NX210c and Glucose in Adults with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Axoltis Pharma

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Ischaemic stroke

Not recruiting

Study on the Safety of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Patients with Acute Ischemic Stroke

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Mesenchymal Stem Cells Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Fingolimod and Interferon Beta-1a in Children with Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fingolimod
  • Sponsor:Novartis Pharma AG

Migraine

Not recruiting

Study on Eptinezumab for Preventing Chronic Migraine in Adults

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Basal cell naevus syndrome

Not recruiting

Study on Patidegib Gel for Reducing Basal Cell Carcinomas in Adults with Gorlin Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Patidegib Hydrochloride Isopropanolate
  • Sponsor:Sol-Gel Technologies Ltd.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.